Chapin Davis’s Moderna MRNA Stock Holding History

Chapin Davis’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-125,539	Closed	-$6.38M	–	276
2026 Q1	$6.38M	Buy	+125,539	New	+$5.86M	1.42%	23

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Chapin Davis's MRNA Position: Q2 2026 in Review

Chapin Davis sold out of Moderna (MRNA) in Q2 2026, closing a stake of 125,539 shares — an estimated $6.38M sold.

Chapin Davis first reported a position in MRNA in Q1 2026 and held it in 1 quarter. The position peaked at $6.38M in Q1 2026. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Chapin Davis reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
Chapin Davis sold 125,539 Moderna shares in Q2 2026, an estimated $6.38M.
Chapin Davis first reported a position in Moderna in Q1 2026 and held it in 1 quarter.
Chapin Davis's Moderna position peaked at $6.38M in Q1 2026.
780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Chapin Davis's 13F filing for Q2 2026, filed 7 Jul 2026.